Cargando…

Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG

BACKGROUND: Recent data suggest the importance of non-neutralizing antibodies (nnAbs) in the development of vaccines against HIV-1 because two types of nnAbs that recognize the coreceptor binding site (CoRBS) and the C1C2 region mediate antibody-dependent cellular-cytotoxicity (ADCC) against HIV-1-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Md Zahid, Hasan, Kuwata, Takeo, Takahama, Shokichi, Kaku, Yu, Biswas, Shashwata, Matsumoto, Kaho, Tamamura, Hirokazu, Matsushita, Shuzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379604/
https://www.ncbi.nlm.nih.gov/pubmed/34419098
http://dx.doi.org/10.1186/s12977-021-00568-y
_version_ 1783741041087610880
author Md Zahid, Hasan
Kuwata, Takeo
Takahama, Shokichi
Kaku, Yu
Biswas, Shashwata
Matsumoto, Kaho
Tamamura, Hirokazu
Matsushita, Shuzo
author_facet Md Zahid, Hasan
Kuwata, Takeo
Takahama, Shokichi
Kaku, Yu
Biswas, Shashwata
Matsumoto, Kaho
Tamamura, Hirokazu
Matsushita, Shuzo
author_sort Md Zahid, Hasan
collection PubMed
description BACKGROUND: Recent data suggest the importance of non-neutralizing antibodies (nnAbs) in the development of vaccines against HIV-1 because two types of nnAbs that recognize the coreceptor binding site (CoRBS) and the C1C2 region mediate antibody-dependent cellular-cytotoxicity (ADCC) against HIV-1-infected cells. However, many studies have been conducted with nnAbs obtained from subtype B-infected individuals, with few studies in patients with non-subtype B infections. RESULTS: We isolated a monoclonal antibody 1E5 from a CRF02_AG-infected individual and constructed two forms of antibody with constant regions of IgG1 or IgG3. The epitope of 1E5 belongs to the C1C2 of gp120, and 1E5 binds to 27 out of 35 strains (77 %) across the subtypes. The 1E5 showed strong ADCC activity, especially in the form of IgG3 in the presence of small CD4-mimetic compounds (CD4mc) and 4E9C (anti-CoRBS antibody), but did not show any neutralizing activity even against the isolates with strong binding activities. The enhancement in the binding of A32, anti-C1C2 antibody isolated from a patient with subtype B infection, was observed in the presence of 1E5 and the combination of 1E5, A32 and 4E9C mediated a strong ADCC activity. CONCLUSIONS: These results suggest that anti-C1C2 antibodies that are induced in patients with different HIV-1 subtype infections have common functional modality and may have unexpected interactions. These data may have implications for vaccine development against HIV-1. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12977-021-00568-y.
format Online
Article
Text
id pubmed-8379604
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83796042021-08-23 Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG Md Zahid, Hasan Kuwata, Takeo Takahama, Shokichi Kaku, Yu Biswas, Shashwata Matsumoto, Kaho Tamamura, Hirokazu Matsushita, Shuzo Retrovirology Research BACKGROUND: Recent data suggest the importance of non-neutralizing antibodies (nnAbs) in the development of vaccines against HIV-1 because two types of nnAbs that recognize the coreceptor binding site (CoRBS) and the C1C2 region mediate antibody-dependent cellular-cytotoxicity (ADCC) against HIV-1-infected cells. However, many studies have been conducted with nnAbs obtained from subtype B-infected individuals, with few studies in patients with non-subtype B infections. RESULTS: We isolated a monoclonal antibody 1E5 from a CRF02_AG-infected individual and constructed two forms of antibody with constant regions of IgG1 or IgG3. The epitope of 1E5 belongs to the C1C2 of gp120, and 1E5 binds to 27 out of 35 strains (77 %) across the subtypes. The 1E5 showed strong ADCC activity, especially in the form of IgG3 in the presence of small CD4-mimetic compounds (CD4mc) and 4E9C (anti-CoRBS antibody), but did not show any neutralizing activity even against the isolates with strong binding activities. The enhancement in the binding of A32, anti-C1C2 antibody isolated from a patient with subtype B infection, was observed in the presence of 1E5 and the combination of 1E5, A32 and 4E9C mediated a strong ADCC activity. CONCLUSIONS: These results suggest that anti-C1C2 antibodies that are induced in patients with different HIV-1 subtype infections have common functional modality and may have unexpected interactions. These data may have implications for vaccine development against HIV-1. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12977-021-00568-y. BioMed Central 2021-08-21 /pmc/articles/PMC8379604/ /pubmed/34419098 http://dx.doi.org/10.1186/s12977-021-00568-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Md Zahid, Hasan
Kuwata, Takeo
Takahama, Shokichi
Kaku, Yu
Biswas, Shashwata
Matsumoto, Kaho
Tamamura, Hirokazu
Matsushita, Shuzo
Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG
title Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG
title_full Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG
title_fullStr Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG
title_full_unstemmed Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG
title_short Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG
title_sort functional analysis of a monoclonal antibody reactive against the c1c2 of env obtained from a patient infected with hiv-1 crf02_ag
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379604/
https://www.ncbi.nlm.nih.gov/pubmed/34419098
http://dx.doi.org/10.1186/s12977-021-00568-y
work_keys_str_mv AT mdzahidhasan functionalanalysisofamonoclonalantibodyreactiveagainstthec1c2ofenvobtainedfromapatientinfectedwithhiv1crf02ag
AT kuwatatakeo functionalanalysisofamonoclonalantibodyreactiveagainstthec1c2ofenvobtainedfromapatientinfectedwithhiv1crf02ag
AT takahamashokichi functionalanalysisofamonoclonalantibodyreactiveagainstthec1c2ofenvobtainedfromapatientinfectedwithhiv1crf02ag
AT kakuyu functionalanalysisofamonoclonalantibodyreactiveagainstthec1c2ofenvobtainedfromapatientinfectedwithhiv1crf02ag
AT biswasshashwata functionalanalysisofamonoclonalantibodyreactiveagainstthec1c2ofenvobtainedfromapatientinfectedwithhiv1crf02ag
AT matsumotokaho functionalanalysisofamonoclonalantibodyreactiveagainstthec1c2ofenvobtainedfromapatientinfectedwithhiv1crf02ag
AT tamamurahirokazu functionalanalysisofamonoclonalantibodyreactiveagainstthec1c2ofenvobtainedfromapatientinfectedwithhiv1crf02ag
AT matsushitashuzo functionalanalysisofamonoclonalantibodyreactiveagainstthec1c2ofenvobtainedfromapatientinfectedwithhiv1crf02ag